FGF9 has complex and important roles in skeletal development and repair. We have previously observed that Fgf9 expression in osteoblasts (OBs) is regulated by G protein signaling and therefore the present study was done to determine whether OB-derived FGF9 was important in skeletal homeostasis. To directly test this idea, we deleted functional expression of Fgf9 gene in OBs using a 2.3kb collagen type I promoter-driven Cre transgenic mouse line (Fgf9 
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Abstract
FGF9 has complex and important roles in skeletal development and repair. We have previously observed that Fgf9 expression in osteoblasts (OBs) is regulated by G protein signaling and therefore the present study was done to determine whether OB-derived FGF9 was important in skeletal homeostasis. To directly test this idea, we deleted functional expression of Fgf9 gene in OBs using a 2.3kb collagen type I promoter-driven Cre transgenic mouse line (Fgf9 
A C C E P T E D M A N U S C R I P T Introduction
The adult skeleton is a dynamic organ that supports body weight and maintains mineral homeostasis through continuous bone remodeling at bone surfaces. This process requires coordinated cellular activities between osteoclast and osteoblast lineage cells, in which osteoblasts are responsible for regulating osteoclasts and depositing bone matrix through perceiving mechanical and biochemical cues, such as hormones and growth factors within bone marrow microenvironment
(1). Parathyroid hormone (PTH) promotes osteoblast function and has emerged as a major approach for clinical treatment of osteoporosis because of its anabolic effects. PTH activates the G s -cyclic AMP signaling pathway by acting on the PTH/PTHrP receptor 1 (PTHR1) in osteoblasts. By assessing the transcriptome of maturing osteoblasts expressing a G s -activating engineered receptor (Rs1) (2,3), we found that fibroblast growth factor 9 (Fgf9) was significantly down-regulated by G s signaling, suggesting a possible role for osteoblast-derived FGF9 in regulating bone homeostasis (4) .
Signaling pathways initiated by the FGF ligand and FGF receptor (FGFR) system are crucial for various cellular processes, including proliferation, differentiation and survival (5) . The functional link between FGF signaling and vertebral limb development has been extensively studied (6) (7) (8) (9) . Signaling through FGFR1 and FGFR2 involve bones arise by intramembraneous ossification and mutations of FGFR1 and 2 principally induce craniosynostosis and facial abnormalities (10, 11) .
Signaling through FGFR3 principally affects bones that arise by endochondral ossification and mutations in FGR3 cause several types of the human skeletal dysplasias including achondroplasia, hypochondroplasia, thanaachondroplasia, and severe achondroplasia (11).
FGF9 expression is localized to perichondrium/periosteum, trabecular bone, and the mesenchyme surrounding developing bones (12) . FGF9 can interact with multiple FGFRs, but has the highest affinity for FGFR3 (6, 13, 14) . FGF9 is reported to have complex and important roles in
skeletal development and repair (10, (15) (16) (17) (18) . For instance, FGF9 null mice exhibit a lethal phenotype with a limb developmental defect that is similar to achondroplasia in human (12) .
Haploinsufficiency of Fgf9 represses bone fracture repair (17) . Conditional over-expression of FGF9 in cartilage caused an inhibitory phenotype of chondrocyte terminal differentiation with less subchondral bone formation (6) . In contrast to its diverse activities in development and physiology, the roles of the FGF9 in bone homeostasis are still unclear due to functional and structural redundancy and the similar receptor specificity across FGF ligands (5, 19) .
In this study, we addressed the physiological role of osteoblast-derived FGF9 by deleting its expression in maturing osteoblasts using the 2.3kb collagen type I promoter driven Cre recombinase. We found that osteoblast-derived FGF9 has a sex dimorphic (male-specific) effect on adult mouse skeleton associated with an increase in osteoblast progenitor cell proliferation and suppression of osteoblast differentiation.
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Materials and Methods
Animals
All transgenic mouse studies were approved by and performed in accordance with the 
Analysis of Bone Formation
Mice were euthanized and femurs and tibiae were removed and dissected free from surrounding musculature. Bones were fixed in 10% neutral-buffered formalin for 48 hours at 4C
and then stored in 70% ethanol before CT and histomorphometry. The distal femurs and tibiofibular junction (TFJ) were scanned using a Scanco VivaCT-50 µCT system (Bruttisellen, Switzerland). All CT images were obtained using an X-ray energy of 55 kV with a voxel size of 
RNA Extraction and RT-qPCR
Both femur and tibia were isolated immediately after animals were euthanized. The epiphyses were then removed and bone morrow was flushed with PBS. The diaphyses were kept frozen in liquid nitrogen until processing. Frozen tissues were pulverized using a biopulverizer (Biospec Products, Inc., Bartlesville, OK, USA), followed by RNA extraction using RNA STAT60
(Tel-Test, Inc., Friendswood, TX, USA) and subsequent purification using Micro-to-Midi Total RNA Purification Kit (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using TaqMan
Reverse Transcription Reagents (Applied Biosystems, Inc., Foster City, CA, USA) and random hexamer primers according to the recommendations of the manufacturer. Gene amplification was measured with SYBR Green using the ABI Prism ViiA TM 7 real-time PCR System (Waltham, MA, USA). Analysis was carried out using the ViiA TM 7 software supplied with the thermocycler. The sequences of the primer sets have been published previously (4, 23, 25) . The target gene expression was displayed normalized to GAPDH.
Serum Chemistry
Before euthanizing the mice, blood was collected from the abdominal inferior vein when mice were under isoflurane inhalation anesthesia and then processed in MicroTainer serum separator tubes (BD Biosciences, San Jose, CA, USA). Serum procollagen type I amino-terminal propeptide (PINP) and serum pyridinoline (PYD) measurements were carried out using the rat/mouse PINP EIA Kit AC-33F1 from Immunodiagnostic Systems (Scottsdale, AZ, USA) and the
Metra Biosystems Serum PYD Kit 8019 (Metra Biosystems Inc., Santa Clara, CA, USA) according to manufacturers' directions.
Bone marrow stromal cell culture and mineralization in vitro
Briefly, the bone marrow plugs from 8 to 10 week old wild type FVB/N mice were flushed out from both femurs and tibiae and cultured in primary culture medium, alpha modification of Eagle's medium (-MEM; Thermo Scientific) supplemented with 10% fetal bovine serum (HyClone), 100U/ml penicillin, 100µg/ml streptomycin (Invitrogen), and 0.25µg/ml Fungizone (26) . Bone marrow stromal cells (BMSCs) were plated into 6-well plates at a density of 1.8 ~ 2.3 x10 6 cells/well. Cells were incubated in a humidified atmosphere of 5% CO 2 at 37°C. On day seven, 50 µg/ml ascorbic acid (Sigma-Aldrich) and 3mM ß-glycerol phosphate (Sigma-Aldrich) were added to the primary culture media to induce osteoblastic differentiation. Media was changed every 2-3 days. To assess mineralization, two percent silver nitrate solution (Sigma-Aldrich) was added to cell culture dishes on day 21 for Von Kossa (VK) staining and UV-crosslinked for 10 minutes.
Stained cultures were scanned and quantified using Improvision Openlab software version 5.0.2.
Cell Proliferation
Effect of FGF9 on mouse BMSC proliferation was determined by measuring BrdU incorporation using a Cell Proliferation ELISA kit (Roche Applied Science, Indianapolis, IN)(23).
Briefly, mouse BMSCs were plated onto 96-well plates at a seeding density of 1x10 4 cells / well in primary culture media. On day 3, 1 ~ 10 ng/ml recombinant mouse FGF9 (R&D Systems, INC, Minneapolis, MN) was added to the media for 24 hours, and BrdU was added 4 hours prior to the assay. The incorporated BrdU in each culture was quantified according to the manufacturer's instruction. The results of this assay were confirmed by repeating the experiment three times.
Protein Extraction and Immunoblotting
The wild type BMSCs at confluence were treated with 5ng/ml FGF9 for 24hr. FGF9
solution was prepared in the osteogenic medium, in which the fetal bovine serum (FBS) was omitted to eliminate the effect of serum components on the phosphorylation of Akt and Akt1.
Whole cells protein lysates were prepared using RIPA buffer (50 mM sodium chloride, 1.0% NP- 
Statistical Analysis
Statistical significance was ascertained by a two-tailed Student's t test or, where indicated, by two-way ANOVA. α ≤ 0.05 was considered significant.
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Loss of Fgf9 in Osteoblasts Decreases Cancellous Bone Formation in Adult Male Bones
To test the specificity of Cre gene expression, we bred the Co l1 (2.3)-Cre mice with a line of Rosa tomato red mice (generously provided by Dr. Ann Zovein, University of California San Francisco, CA) (Fig 1B) . The Cre recombinase is demonstrated to be expressed in OBs and osteocytes (OCTs) in adult Coll (2.3)-Cre; td/Tomato Red mice (Fig 1B) . To test the efficiency of Fgf9 deletion in Fgf9 OB-/-mice, we also performed reverse transcription end point PCR on RNA extracted from long bones and demonstrated that FGF9 gene was successfully excised by Cre recombinase (Fig. 1C)(20) and as expected, the conditional Cre-loxp recombination dramatically decreased Fgf9 mRNA level in both male and female Fgf9 OB-/-mice (Fig. 1D) .
MicroCT assessment demonstrated that Fgf9 deletion led to a dramatic decrease in cancellous bone fractional volume (BV/TV) at distal femur in male, but not female, Fgf9 OB-/-mice ( Fig. 2A and Table 1 ). The decrease was mainly associated with a significant decrease in trabecular thickness (Tb.Th) (p<0.001) and an increase in trabecular separation (Tb.Sp) ( Table. 1 ).
In contrast, Fgf9 deficiency did not change trabecular number (Tb.N) ( Table. 1 (Fig. 2B) .
However, the female transgenic mice displayed no change in BV/TV, Tb.Th, Tb.N, and Tb.Sp at the distal femur (Fig. 2B) . The osteoblasts sitting at the trabecular surface (N.Ob/BS) was also counted. It was found that N.Ob/BS was significantly lower in the male but not in the female Fgf9 fl/fl mice, compared to the age-matched controls (Supplemental Fig. 1A) .
To reveal the mechanism by which the loss of Fgf9 in osteoblasts led to decreased cancellous factional bone volume, we performed dynamic histomorphometry on the same bones (Fig. 2C) . A sexual dimorphic response of bone formation to the Fgf9 deletion in osteoblasts was also observed at the distal femur by measuring fluorescence labeled trabecular surfaces (Fig. 2C) .
Male Fgf9
OB-/-mice displayed decreased MS/BS and BFR. However, trabecular MAR was not altered in male Fgf9 OB-/-mice. In contrast, there were no differences seen in the parameters of dynamic histomorphometry between female Fgf9 OB-/-mice and sex matched littermate control mice (Fig. 2C) .
Loss of Fgf9 in Osteoblasts Decreases Cortical Bone Formation in Adult Male Bones
The cortical bone shell is a key determinant of bone strength and fracture risk and thins rapidly with age (27, 28) . Effects of the conditional knockout of FGF9 on cortical bone volume, cortical bone thickness, and bone marrow area were assessed at the TFJ by µCT (Fig. 3A and Table 1 .). In male mice, there was no difference in tissue volume between the knockout and the littermate control mice. However, the FGF9 deletion resulted in a slight and statistically significant decrease in bone volume and cortical bone thickness (Ct. Th). There were no significant differences observed between female control and transgenic mice ( Table 1. ). The changes in cortical bone were further confirmed by histological analysis of the TFJ in Fgf9 OB-/- (Fig. 3B) . In males, loss of Fgf9 in osteoblasts did not affect the cortical periosteal perimeter. The endosteal perimeter and bone marrow area were significantly greater while cortical thickness was significantly smaller at the TFJ
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OB-/-mice (Fig. 3B) . This result demonstrates that the loss of bone that occurred at the TFJ was mainly at the endosteal surface. The decreased bone formation at both periosteal and endosteal surfaces of the TFJ was mainly due to the decreased mineralizing surface in male Fgf9
OB-/-. There were no significant changes in any of the cortical parameters in female mice (Fig. 3C) . In addition, it has been found that the Ps.BFR is decreased in Fgf9 OB-/-male mice without any significant changes in periosteal perimeter (Ps.Pm) (Fig. 3B and 3C) . The mice used in this study were at age of 3 months and by then the peak bone mass has already been established (29) . Our result suggests that the source of FGF9 from mature osteoblasts possibly does not impact the cortical bone accrual during growth but may affect the cortical bone expansion during aging.
Endogenous Fgf9 Restrains the Function of Mature Osteoblasts
We examined the effects of FGF9 deletion on the expression of genes in the femoral diaphysis. We observed no change in the expression of the early osteogenic marker genes, such as Osx and Runx2. Surprisingly, Alp, Col1, Ocn, and Dmp1 mRNA expression was significantly higher in male Fgf9
OB-/-, compared to age-matched Fgf9 fl/fl mice. There were no significant differences observed between female transgenic and control mice, in regards to gene expression (Fig. 4) . It has been reported that Fgf9 is important for promoting skeletal vascularization and global Fgf9 null mice displayed delayed osteogenesis due to defects in angiogenesis (12) . However, we did not detect a significant change pecam1 mRNA level in the Fgf9 OB-/-mice (data not shown).
Bone Resorption in Adult Fgf9
OB-/-Mouse Bone Was not Altered
In a previous study, Fgf9 null mice were found to display a reduction in osteoclast numbers in the perchondrondrium and primary spongiosa of the developing long bones (12) . To examine if
Fgf9 deficiency in osteoblasts affects osteoclastogenesis in adult skeleton, we performed TRAP staining and found that the specific deletion of Fgf9 in osteoblasts did not alter the number of osteoclasts (N.Oc/BS) within the distal femur (Fig. 5) . Consistent with this finding, serum PYD was
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13 not changed, either (Fig. 5) . Although the levels of Opg and Rankl mRNA were increased in males (data not shown), the ratio of OPG/RANKL was not significantly altered by deleting Fgf9 (Fig. 5) .
Exogenous FGF9 Stimulates Proliferation of BMSCs
We demonstrated that Fgf9 OB-/-mice displayed an osteoblastic phenotype, in which deletion of Fgf9 in osteoblasts led to a low bone mass due to a decreased bone formation rate in male skeleton. We have carried out additional studies to determine whether there is a cell autonomous autocrine role for FGF9 in promoting osteogenesis. We found that bone marrow stromal cells derived from male Fgf9 OB-/-mice displayed osteogenic differentiation that was comparable to that seen in cultures from WT mice (Supplemental Figure 1B) . These findings suggest that osteoblast derived FGF9 promotes osteogenesis through paracrine effects on osteoprogenitors. To test this hypothesis, we cultured BMSCs from wild type mice and the effect of exogenous FGF9 on BMSC proliferation was examined using a BrdU incorporation assay. It was found that treatment with rmFGF9 for 24 hrs significantly increased proliferation in both male and female BMSCs in a dose dependent manner (Fig. 6A) . Strikingly, BMSCs from male mice were more responsive to FGF9 than were BMSCs from female mice. At a dose of 5 ng/ml rmFGF9, there was a 209% (p<0.01) increase in BrdU labeled male cells and a 76% (p<0.05) increase in BrdU labeled female cells, when compared to sex matched, vehicle treated control cells (Fig. 6A) .
We have examined the expression levels of FGFR3 in both bone marrow progenitors (PCs) and mature osteoblasts (OBs) because FGF9 has the highest affinity for FGFR3 (6, 13, 14) . It was found that the expression level of FGFR3 mRNA was much higher in mature OBs regardless of gender and genotype (supplemental Fig. 2A) . We also assessed whether exogenous FGF9 would produce anabolic effects in maturing OBs due to their high level of expression of FGFR3. In this study, the BMSCs from male and female wild type mice were cultured separately. FGF9 at a dose of 5ng/ml was administered to OBs from day 14 to day 21 post culture, mRNA levels of the
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14 osteogenic marker genes including osterix, Runx2, alkaline phosphatase, type 1 collagen and osteocalcin were measured using real time PCR. It was found that mRNA levels of these bone marker genes were decreased by FGF9 treatment regardless of gender (Supplemental Fig. 2B and   2C ).
FGF9 Stimulates Proliferation of BMSCs through Akt1 Signaling Pathway
Inhibition of Akt activity by adding the Akt inhibitor MK-2206 (1µM) completely eliminated the stimulatory effect of FGF9 on osteoblast precursor proliferation in vitro (Fig. 6B) .
Additionally, levels of Akt1and phosphorylated Akt1 in the confluent BMSCs treated with FGF9
were measured by western blot. It was found that exogenous FGF9 stimulated BMSC proliferation by mainly increasing phosphorylation of Akt1 (Fig. 6C) , a result in line with the previous finding that loss of Akt1 was shown to be deleterious to osteoblast precursor development, leading to lower bone mass in male (but not female) mice (30) .
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Discussion
FGF9 is critical for skeletal development (6) (7) (8) (9) . It has been reported that FGF9 is expressed in the proximity of the developing skeleton and that FGF9 null mice exhibited a limb phenotype with rhizomelia (12) . FGF9 is expressed at low levels in osteoprogenitor cells, but is highly expressed in mature osteoblasts (31) . The physiological role of osteoblast-derived FGF9 in skeletal homeostasis is unknown. Our results show that deletion of Fgf9 in osteoblasts led to a significant decrease in both cancellous and cortical bone in young adult male mice. Surprisingly, the specific deletion of FGF9 had no such effect in female mice. We have previously observed that Fgf9 expression in osteoblasts is regulated by G protein signaling (4) . Activation of Gs signaling or increasing intracellular level of cAMP, both conditions producing strong bone formation (2,3), down-regulated the expression of Fgf9 in mature osteoblasts. This led us to hypothesize that osteoblast-derived FGF9 might play a negative role in skeletal anabolism. However, deletion of Fgf9 in osteoblasts resulted in an osteopenic phenotype, as evidenced by a decreased trabecular bone fractional volume with decreased bone formation at trabecular bone surfaces in male Fgf9
OB-/-mice. Histomorphometry also demonstrated that FGF9 deficiency resulted in a decrease in number of OBs and mineralized surface (MS/BS) but had no effect on MAR at the distal femur, suggesting that deletion of FGF9 in osteoblasts might not affect the speed of mineralization, but the number of osteoblasts, at the trabecular surface. In the diaphysis of long bones (where mature osteoblasts and osteocytes are the dominant osteoblast lineage cell types) loss of Fgf9 led to increased expression of markers of mature osteoblasts, including Ocn, Dmp1, and Col1. However, the male Fgf9 OB-/-mice exhibited a decreased cortical bone thickness with a decreased cortical bone formation rate.
Collectively, these findings suggest that mature osteoblasts serve as an important source of FGF9
and that secreted FGF9 regulates bone formation in adult male mice in a cell non-autonomous manner.
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FGFs including FGF9 comprise the most common subfamily that transduces signals through FGFR tyrosine kinases. These polypeptides can be retained in the extracellular matrix in the vicinity of their secreting cells and act as autocrine and/paracrine factors (32, 33) . In previous studies, exogenous FGF9 has been demonstrated to be pro-osteogenic and to facilitate bone regeneration (17, 18) . Recently, FGF9 has been found to induce osteoblast proliferation and new bone formation in a bone organ assay (34) . In the present study, we demonstrated that exogenous FGF9 stimulates bone marrow stromal cell proliferation in a dose dependent manner, a finding similar to that of Lu et al. (35) . These findings support the hypothesis that osteoblast secreted FGF9 serves as a paracrine role to stimulate osteogenesis of bone marrow skeletal stem cells to maintain bone homeostasis.
Akt1 deficiency is reported to decrease bone mass and formation (30, 36) . FGF9 has been demonstrated to activate Akt pathways to stimulate steroidogenesis in mouse Leydig cells (37).
Akt1 is the major isoform in bone cells and acts to suppress osteoblast apoptosis (36) . In the present study, we demonstrated that FGF9 stimulates the proliferation of BMSCs by activating Akt1.
It is not clear why loss of Fgf9 in osteoblasts resulted in significant bone loss in male mice while not affecting the female skeleton. Available evidence suggests that there is a collaborative interaction between FGF9 and the actions of androgens on bone (30, 38, 39) . Firstly, FGF9 has functions related to sex domination in addition to bone formation. Mice globally lacking Fgf9 display male-to-female sex reversal (40) . Secondly, androgens promote proliferation of osteoblast progenitors and differentiation, in part, through PI3-kinase-Akt signaling pathway (30, 41) . Of interest in this regard, global haploinsufficiency of Akt1 in mice also induced a decrease in femoral bone mass that was seen in males but not females (30) . Thirdly, we have demonstrated that FGF9
stimulates the proliferation of BMSCs by activating Akt1. Finally, androgens have potent effects on osteoblast formation. While androgens maintain trabecular bone mass and integrity, they favor periosteal bone formation in men (42) . These findings are consistent with the bone phenotype of The effects of FGF9 on osteoblasts and progenitors are complex. In addition to delivering a mitogenic signal in a variety of cells, FGF9 is also involved in cell differentiation, motility, and survival (43) . Experiments have suggested that FGF9 serves as an endogenous inhibitor of chondrocyte differentiation (6, 44) . However, the role of FGF9 on the differentiation of OBs is not clear. FGF9 is known to signal mainly through FGFR3 in bone (13) . In this study, we found that the expression levels of FGFR3 were higher in mature OBs than bone marrow progenitor cells, independent of gender and genomic difference (Supplemental Figure 2A ) and that addition of 
